Indegene Ltd
Indegene Ltd (INDGN) last traded at ₹564, a market capitalisation of ₹13,595 crore, on a P/E of 32.7. Over the past 52 weeks the stock has ranged between ₹414 and ₹597. Indegene Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1,063 crore and net profit of ₹116 crore. Figures are as of 25 Aug 2026 and are not real time.
Indegene Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Indegene Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,063 cr, up 39.7% from ₹761 cr a year earlier. Net profit was ₹116 cr, up 0.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 |
| Expenses | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 |
| Operating profit | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 |
| OPM % | 18% | 18% | 20% | 20% | 17% | 17% | 16% | 16% |
| Other income | 21 | 38 | 26 | 22 | 20 | 19 | -10 | 29 |
| Interest | 4 | 3 | 3 | 4 | 4 | 5 | 7 | 6 |
| Depreciation | 19 | 20 | 21 | 22 | 23 | 40 | 42 | 44 |
| Profit before tax | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 |
| Tax % | 26% | 25% | 21% | 23% | 23% | 24% | 24% | 24% |
| Net profit | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 |
| EPS (₹) | 3.83 | 4.58 | 4.90 | 4.85 | 4.25 | 4.28 | 3.31 | 4.82 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Indegene Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 966 | 1,665 | 2,306 | 2,590 | 2,839 | 3,510 | 3,813 |
| Operating profit | 230 | 287 | 396 | 505 | 548 | 619 | 638 |
| OPM % | 24% | 17% | 17% | 20% | 19% | 18% | 17% |
| Net profit | 149 | 163 | 266 | 337 | 407 | 401 | 401 |
| EPS (₹) | 951.96 | 937.73 | 11.99 | 15.14 | 16.95 | 16.65 | 16.66 |
TTM is the trailing twelve months to the most recent quarter.
Indegene Ltd growth and returns
- 10 Years
- %
- 5 Years
- 29%
- 3 Years
- 15%
- TTM
- 30%
- 10 Years
- %
- 5 Years
- 23%
- 3 Years
- 16%
- TTM
- -4%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 0%
- 10 Years
- %
- 5 Years
- 21%
- 3 Years
- 19%
- Last Year
- 14%
Indegene Ltd shareholding pattern
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| FIIs | 4.82% | 5.03% | 5.24% | 10.04% | 11.30% | 11.48% | 10.27% | 9.92% |
| DIIs | 3.17% | 3.99% | 4.96% | 7.20% | 6.95% | 8.06% | 8.29% | 8.74% |
| Public | 92.01% | 91.01% | 89.80% | 82.75% | 81.74% | 80.44% | 81.43% | 81.34% |
| No. of shareholders | 1,51,440 | 1,53,789 | 1,44,708 | 1,51,997 | 1,51,809 | 1,47,182 | 1,42,119 | 1,38,533 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Indegene Ltd corporate filings
- Intimation of Investors / Analysts MeetingCompany Updatelow impact
Cruxal's analysis: Indegene Ltd has issued an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - Update on Material Litigation under the Telephone Consumer Protection Act, 1991 involving Wholly-Owned Subsidiary, Indegene, Inc.Company Updatelow impact
Cruxal's analysis: Indegene Ltd has issued a regulatory update regarding ongoing material litigation…
Read the full analysis - Transcript of the 28th Annual General Meeting held on August 13, 2026AGM/EGMmedium impact
Cruxal's analysis: Indegene Limited's 28th AGM transcript outlines a strategic pivot toward AI-embedded…
Read the full analysis - Appointment of Ms. Jill Mary De Simone (DIN: 11483134) as an independent Director of the CompanyCompany Updatelow impact
Cruxal's analysis: Indegene Limited has confirmed the shareholder approval for the appointment of Ms. Jill…
Read the full analysis - Scrutinizer''s Report - 28th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Indegene Limited has successfully concluded its 28th Annual General Meeting held on…
Read the full analysis - Intimation of Investors / Analysts MeetingCompany Updatelow impact
Cruxal's analysis: Indegene Ltd has filed an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - Proceedings of the 28th Annual General Meeting of the CompanyAGM/EGMlow impact
Cruxal's analysis: Indegene Limited has successfully concluded its 28th Annual General Meeting held on…
Read the full analysis - Intimation of Investors / Analysts MeetingCompany Updatelow impact
Cruxal's analysis: Indegene Ltd has filed an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - Intimation of Investors / Analysts MeetingCompany Updatelow impact
Cruxal's analysis: Indegene Ltd has issued an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I- A SPV LtdInsider Trading / SASTmedium impact
Cruxal's analysis: Indegene Limited has witnessed a complete exit by BPC Genesis Fund I-A SPV Limited, which…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I SPV LtdInsider Trading / SASTmedium impact
Cruxal's analysis: Indegene Limited faces a significant liquidity event as BPC Genesis Fund I SPV Ltd has…
Read the full analysis - Transcript of earnings conference call on financial results for the quarter ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: Indegene Limited reported Q1 FY27 revenue of 1,063.1 crore, reflecting a 39.7% YoY growth…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Indegene Ltd
Cruxal reads every Indegene Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.